In Section A, contributors will receive distinctive doses and schedules of oral ABBV-744 tablet to identify Risk-free dosing program. Extra individuals might be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. In Segment C, https://abbv-744preclinicalstudie36790.blogpixi.com/32349021/the-2-minute-rule-for-abbv-744-in-the-treatment-of-drug-resistant-cancers